Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia

Int J Hematol. 2015 Nov;102(5):639-42. doi: 10.1007/s12185-015-1824-y. Epub 2015 Jul 2.

Abstract

Imatinib is generally well tolerated, but gastric antral vascular ectasia (GAVE) remains a rare but significant complication of imatinib therapy. Whilst this complication has been described in other disease settings, only one other case of GAVE has been reported in a chronic myeloid leukaemia (CML) patient receiving imatinib. Herein, we present three CML patients with GAVE complicating imatinib therapy. In all cases, GAVE resolved only with cessation of imatinib. This confirms a causal relationship between GAVE and imatinib. GAVE should be considered as a possible cause of anaemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.

Keywords: Chronic myeloid leukaemia; Gastric antral vascular ectasia; Imatinib; Tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Female
  • Gastric Antral Vascular Ectasia / chemically induced*
  • Gastric Antral Vascular Ectasia / pathology*
  • Humans
  • Imatinib Mesylate / administration & dosage*
  • Imatinib Mesylate / adverse effects*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Middle Aged

Substances

  • Imatinib Mesylate